Medical isotope producer Advanced Medical Isotope (AMIC) has signed an option agreement with Battelle Memorial Institute for the rights to an injectable polymer for high-dose interstitial radiation therapy.
Radiogel is a microsphere-embedded polymer solution designed to maximize the radiation dose to cancerous tumors that cannot be removed surgically.
AMIC will have the exclusive right to further develop the technology, which has been developed by Battelle-managed Pacific Northwest National Laboratory, when it exercises the option and executes an exclusive license with Battelle.
Radiogel will be administered percutaneously or intraoperatively for treating solid tumors that cannot be removed safely by surgical excisions. It is expected to include an injectable, water-based polymer that delivers yttrium-90 microspheres directly into tumor tissues.
The combination of insoluble yttrium-90 microspheres and the Radiogel carrier is expected to deliver maximally achievable therapeutic indices at a low cost, AMIC said.
